Logo image
New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease
Journal article   Peer reviewed

New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease

Young-Cho Kim, Stephanie Alberico, Eric Emmons and Nandakumar Narayanan
Frontiers in biology, Vol.10(3), pp.230-238
06/2015
DOI: 10.1007/s11515-015-1360-4
PMCID: PMC5340264
PMID: 28280503
url
https://www.ncbi.nlm.nih.gov/pmc/articles/5340264View
Open Access

Abstract

The neurotransmitter dopamine acts via two major classes of receptors, D1-type and D2-type. D1 receptors are highly expressed in the striatum and can also be found in the cerebral cortex. Here we review the role of D1 dopamine signaling in two major domains: L-DOPA-induced dyskinesias in Parkinson’s disease and cognition in neuropsychiatric disorders. While there are many drugs targeting D2-type receptors, there are no drugs that specifically target D1 receptors. It has been difficult to use selective D1-receptor agonists for clinical applications due to issues with bioavailability, binding affinity, pharmacological kinetics, and side effects. We propose potential therapies that selectively modulate D1 dopamine signaling by targeting second messengers downstream of D1 receptors, allosteric modulators, or by making targeted modifications to D1-receptor machinery. The development of therapies specific to D1-receptor signaling could be a new frontier in the treatment of neurological and psychiatric disorders.
Life Sciences Biochemistry, general Genetics and Population Dynamics D1DR cognition Proteomics Neurobiology Developmental Biology dyskinesia dopamine D1 receptor Cell Biology

Details

Metrics

18 Record Views
Logo image